AIC
ALDR

Ameritas Investment Company’s Alder Biopharmaceuticals ALDR Stock Holding History

Ameritas Investment Company’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-41
Closed -$1K – 972
2019
Q1 		$1K Buy
+41
New +$531 ﹤0.01% 923

Other funds holding ALDR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ameritas Investment Company's ALDR Position: Q2 2019 in Review

Ameritas Investment Company sold out of Alder Biopharmaceuticals (ALDR) in Q2 2019, closing a stake of 41 shares — an estimated $1K sold.

Ameritas Investment Company first reported a position in ALDR in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 127 funds tracked by Wall St. Rank hold ALDR as of Q2 2019.

  • Ameritas Investment Company reported no remaining Alder Biopharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Ameritas Investment Company sold 41 Alder Biopharmaceuticals shares in Q2 2019, an estimated $1K.
  • Ameritas Investment Company first reported a position in Alder Biopharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Ameritas Investment Company's Alder Biopharmaceuticals position peaked at $1K in Q1 2019.
  • 127 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2019.

Based on Ameritas Investment Company's 13F filing for Q2 2019, filed 7 Aug 2019.